Lisa Manig1, Stefan Janssen1, Steven E Schild2, Dirk Rades3. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 3. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.
Abstract
BACKGROUND/AIM: To develop an instrument that could estimate the 1-year survival probabilities of patients irradiated for recurrent carcinoma of the bladder. PATIENTS AND METHODS: Thirty patients irradiated for locally recurrent bladder carcinoma were included. Six pre-treatment factors [age, gender, Karnofsky score (KPS), pack years, grading and time between cancer diagnosis and radiotherapy] were evaluated for survival. Of those factors showing a trend or significance on multivariate analysis, 1-year survival rates were added. RESULTS: On multivariate analysis, KPS was significant (hazard ratio(HR)=3.76, p=0.008), age showed a trend (HR=2.04, p=0.13). Patient scores were five, nine, ten or fourteen points with 1-year survival rates of 13%, 25%, 57% and 82% (p=0.003). Three groups were designed, A (5-9 points), B (10 points) and C (14 points) with 1-year survival rates of 17%, 57% and 82% (p=0.001). CONCLUSION: This score, including three groups with different 1-year survival probabilities, can aid physicians treating patients with recurrent bladder carcinoma. Copyright
BACKGROUND/AIM: To develop an instrument that could estimate the 1-year survival probabilities of patients irradiated for recurrent carcinoma of the bladder. PATIENTS AND METHODS: Thirty patients irradiated for locally recurrent bladder carcinoma were included. Six pre-treatment factors [age, gender, Karnofsky score (KPS), pack years, grading and time between cancer diagnosis and radiotherapy] were evaluated for survival. Of those factors showing a trend or significance on multivariate analysis, 1-year survival rates were added. RESULTS: On multivariate analysis, KPS was significant (hazard ratio(HR)=3.76, p=0.008), age showed a trend (HR=2.04, p=0.13). Patient scores were five, nine, ten or fourteen points with 1-year survival rates of 13%, 25%, 57% and 82% (p=0.003). Three groups were designed, A (5-9 points), B (10 points) and C (14 points) with 1-year survival rates of 17%, 57% and 82% (p=0.001). CONCLUSION: This score, including three groups with different 1-year survival probabilities, can aid physicians treating patients with recurrent bladder carcinoma. Copyright
Authors: Deepak Kilari; Kenneth A Iczkowski; Chintan Pandya; Adam J Robin; Edward M Messing; Elizabeth Guancial; Eric S Kim Journal: Anticancer Res Date: 2016-02 Impact factor: 2.480
Authors: Dirk Rades; Stefan Huttenlocher; Niklas Gebauer; Dagmar Hornung; Ngo Thuy Trang; Mai Trong Khoa; Steven E Schild Journal: Anticancer Res Date: 2015-06 Impact factor: 2.480
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Christian Weiss; Michael Wittlinger; Dirk G Engehausen; Frens S Krause; Oliver J Ott; Jürgen Dunst; Rolf Sauer; Claus Rödel Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-01 Impact factor: 7.038
Authors: Dirk Rades; Liesa Dziggel; Lisa Manig; Stefan Janssen; Mai Trong Khoa; Vuong Ngoc Duong; Vu Huu Khiem; Steven E Schild Journal: In Vivo Date: 2018 May-Jun Impact factor: 2.155